YUYoshiaki Uyama

Yoshiaki Uyama

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yoshiaki Uyama has a total of 184 co-authors. Here are the top co-authors by number of shared publications:

  • Toyotaka Iguchi

    Office of Pharmacovigilance II Pharmaceuticals and Medical Devices Agency Tokyo Japan

    14 shared publications
  • Chieko Ishiguro

    Office of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan

    12 shared publications
  • Kazuhiro Kajiyama

    Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan

    12 shared publications
  • Naoya Horiuchi

    Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan

    11 shared publications
  • Takahiro Nonaka

    Dokuritsu Gyosei Hojin Iyakuhin Iryo Kiki Sogo Kiko

    9 shared publications
  • Hideki Hanaoka

    Department of Regulatory Science of Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan

    8 shared publications

Latest Publications

  • Open Access

    Operationalizing ICH E17 in Multiregional Clinical Trials: A Practical Roadmap for AI ‐Enabled and Quantitative Methods as Enabling Tools

    by Rominder Singh, Yoshiaki Uyama, Aloka Chakravarty, I‐Chun Lai, Jared Auclair

    ICH E17 harmonized the design and interpretation of multiregional clinical trials (MRCTs), yet almost a decade after adoption, its operationalization remains inconsistent across several areas: regional definition, assessment of regional heterogeneity, evaluation of intrinsic and extrinsic factors, pooling, bridging and extrapolation, and integration of real‐world data. This White Paper offers a practical roadmap for operationalizing ICH E17 across the MRCT lifecycle (planning, conduct, and submission) in which artificial intelligence (AI), pharmacometric, and biostatistical methods are treated as enabling tools rather than as the primary subject. In this paper, for each decision point, we frame a context of use, decision consequence, validation expectation, bias assessment, documentation need, and likely regulatory engagement pathway, and we distinguish approaches that are usable today for operational support from those that may provide supportive evidence with appropriate validation and those that remain exploratory. We do not propose specific regulatory recommendations; rather, we intend this roadmap to stimulate cross‐stakeholder discussion and the accumulation of shared, well‐documented use cases that could, in time, inform future implementation‐oriented guidance.

  • Open Access

    Proactive adoption of generative artificial intelligence (AI) in the operations of Japan's Pharmaceuticals and Medical Devices Agency (PMDA): Current initiatives, governance, and future perspectives

    by Kohei Amakasu, Junichi Kawana, Osamu Kotera, Tomoharu Numanyu, Akihiro Nakajima, Koichi Ishikawa, Yuka Kobayashi, Yoshiaki Uyama

    The Pharmaceuticals and Medical Devices Agency (PMDA) continues to face increasing operational demands stemming from growing regulatory complexity, expanding data volumes, and evolving scientific and societal expectations. In this context, the appropriate adoption of generative artificial intelligence has emerged as a potential approach for enhancing operational efficiency while reinforcing scientific rigor and accountability. This article describes the current status of generative artificial intelligence utilization at PMDA, outlines its governance framework, and discusses future perspectives for its sustainable application based on institutional experience, internal policy development, and planned/ongoing proof-of-concept activities conducted within PMDA. We summarize a phased implementation strategy that combines commercially available generative artificial intelligence tools for administrative support with the exploration of large language models in secure internal environments for scientifically specialized tasks. Central to this approach is a governance framework that emphasizes human-in-the-loop decision-making, staged evaluation, information governance, and staff capacity building. We also present practical use cases across information collection, analysis and evaluation, and dissemination activities to illustrate how generative artificial intelligence may support regulatory work without replacing human judgment. In conclusion, PMDA's experience suggests that proactive yet cautious adoption of generative artificial intelligence, grounded in robust governance and organizational learning, can improve productivity and enhance scientific capacity within regulatory authorities while maintaining public trust and institutional accountability.


  • Open Access

    Present and Future Post-marketing Drug Safety Assessment in Japan: A PMDA Perspective

    by Takashi Waki, Shinya Watanabe, Takashi Ando, Kazuhiro Kajiyama, Koichi Fukuda, Eiko Iwasa, Yukari Iwasaki, Masao Iwagami, Taihei Tanaka, Daisuke Maeda, et al.

    For pharmacovigilance, the Pharmaceuticals and Medical Devices Agency in Japan has utilized real world data (RWD) from multiple sources, including individual case safety reports, and medical information databases that capture routinely collected data from clinical practice. These RWD have their own characteristics with advantages and disadvantages. In this commentary, we describe current and future direction of post-marketing drug safety assessment in Japan.


  • Open Access

    Editorial: Advancement of RWD/RWE utilization for enhancing drug development and benefit/risk assessment

    by Yoshiaki Uyama, Anick Bérard, K Arnold Chan

    Real-world data (RWD) and real-world evidence (RWE) have been utilized not only for drug safety assessment but also for effectiveness evaluation for drug approval on a global basis and many cases of RWD/RWE utilization for regulatory purposes have been accumulated with more diversifications in terms of data sources, methodology and study region (Kajiyama et al., 2024;Asano et al., 2025;Bachinger et al., 2025;Innes et al., 2025). Scientific discussions toward international harmonization related to RWD/RWE In conclusion, this research topic reflects a field of RWD/RWE utilization in transition from merely using RWD to actively strengthening RWE for decision-making use. The five studies provide a multifaceted view of the current state and emerging

  • Open Access

    Safety Comparison of Risk of Liver Dysfunction between Generic and Brand Statin Drugs Marketed in Japan: A Cohort Study Using MID-NET®

    by Hotaka Maruyama, Yuki Kinoshita, Takashi Ando, Jun Okui, Maki Komamine, Kazuhiro Kajiyama, Naoya Horiuchi, Yoshiaki Uyama

    To verify safety profiles of generic statins in a real-world setting, the risk of liver dysfunction as a common adverse event was compared between generic and brand drugs. A new user cohort design was employed in which patients prescribed one of six statins (atorvastatin, simvastatin, pitavastatin, pravastatin, fluvastatin, or rosuvastatin) in Japan between January 1, 2014 and March 31, 2022 were identified in the MID-NET ® database. Adjusted hazard ratios (aHRs) for generic drugs compared with their corresponding brand drug for the occurrence of first liver dysfunction were estimated using high-dimensional propensity score-weighted Cox models. Among the six statins, no increased trends in aHRs were observed in the primary analysis, except for atorvastatin. The primary analysis showed an aHR of 2.08 (95% confidence interval [CI]: 1.20–3.63) for atorvastatin. In an additional analysis with shorter follow-up periods, aHRs for atorvastatin gradually approached 1.00 (1.74 [95% CI: 0.94–3.22] within 360 days, 1.65 [95% CI: 0.84–3.25] within 180 days, 1.49 [95% CI: 0.73–3.01] within 90 days, and 1.33 [95% CI: 0.60–2.96] within 30 days). Results suggest that risks of liver dysfunction by generic statins are similar to those for brand drugs, facilitating our understanding about the safety of generic drugs. The aHR for atorvastatin was inconsistent between the primary and additional analyses, which suggests that the observed increased risk of generic atorvastatin may be affected by other factors and does not necessarily indicate a different safety profile between generic and brand drugs.


  • Open Access

    Development and Validation of Interstitial Lung Disease Identification Algorithms in Japan’s Post-Marketing Drug Safety Surveillance Platform, MID-NET®

    by Masatoshi Tanigawa, Wakako Horiki, Takahiro Nonaka, Hotaka Maruyama, Koichiro Takahashi, Hironori Sadamatsu, Yuki Kurihara, Ryusuke Inoue, Yoko Kataoka, Hiroaki Dobashi, et al.

    Purpose : To develop and validate algorithms for the identification of interstitial lung disease (ILD) in Japan’s medical information database network, MID-NET ® . Methods : A total of 375 possible ILD cases at three hospitals were initially identified from MID-NET ® . Two independent physicians conducted a medical review to confirm or rule out the diagnosis at each hospital. The positive predictive value (PPV) and relative sensitivity (rSe) of seven ILD identification algorithms, incorporating diagnostic codes, prescribed medications (steroids, immunosuppressive agents, and anti-fibrotic agents), laboratory test values (KL-6 and SP-D), and CT imaging records, were then evaluated against the medical review. Results : The PPV for the seven algorithms ranged from 54.3% to 100.0%, while rSe ranged from 6.8% to 76.5%. A trade-off was observed between PPV and rSe. Algorithm-3 , which limited cases to confirmed diagnosis or mandatory diagnosis fields, demonstrated a good balance between PPV (61.8%) and rSe (57.6%). Adding laboratory values to Algorithm-3 yielded higher PPVs of approximately 72% in Algorithms-4 and 5, but with some reduction in rSe. The source of diagnosis code and use of anti-fibrotic agents had the greatest impact on PPV and rSe. Medical review showed high inter-rater agreement, with Cohen’s kappa statistic of 0.90 (95% confidence interval: 0.87–0.95). Conclusion : This study analyzed seven ILD identification algorithms, with the most optimal being those that included the required diagnostic fields. These findings support the use of validated algorithms for outcome identification in pharmacovigilance and clinical research.

  • Open Access

    Risk of liver dysfunction with ACE inhibitors based on real-world data from the MID-NET® in Japan

    by Yuki Kinoshita, Takashi Ando, Kazuhiro Kajiyama, Hotaka Maruyama, Mei Kohama, Ayumi Tanaka, Yusuke Matsunaga, Chieko Ishiguro, Takahiro Nonaka, Naoya Horiuchi, et al.

    Warnings about liver dysfunction in Japanese package inserts vary among angiotensin-converting enzyme (ACE) inhibitors, and risk assessment of liver dysfunction with ACE inhibitors has been limited. To evaluate the risk of liver dysfunction among patients prescribed ACE inhibitors available in Japan, we conducted this study based on the real-world data from MID-NET ® . We identified patients who were newly prescribed ACE inhibitors between January 1, 2009 and December 31, 2019 and excluded patients with liver dysfunction before the first prescription of ACE inhibitors. To compare the risk of liver dysfunction between the control group (enalapril maleate) and each exposure group, a pairwise Cox proportional hazards model was employed to estimate the hazard ratio (HR) adjusted by inverse probability weighting based on the high-dimensional propensity score. A total of 29,817 patients were identified for analysis in the cohort. Compared with the control group, the HRs (95% confidence interval) were 1.37(0.79–2.38) for captopril, 0.71(0.33–1.54) for alacepril, 0.72(0.55–0.93) for imidapril hydrochloride, 1.08(0.86–1.34) for perindopril erbumine, and 0.69(0.52–0.91) for lisinopril hydrate. The risk of liver dysfunction with ACE inhibitors is unlikely to be a class-effect. Although continuous safety monitoring is necessary for promoting proper use of ACE inhibitors, the results indicate that no additional safety measures are currently required for ACE inhibitors that do not carry a liver dysfunction-related warning in Japan.

  • Open Access

    Japan's Perspective on Facilitating Drug Development Through Asian Cooperation in Multi‐Regional Clinical Trials: Insights From Regulatory Research

    by Masahiro Tohkin, Yoshiro Saito, Yoshiaki Uyama

    Multi‐regional clinical trials (MRCTs) have recently become a popular strategy for novel drug development, contributing to the early access to novel medicines in participating regions by enhancing development efficiency. To further facilitate MRCTs in Asia, the Japanese government has financially supported research activities in Japan for over 15 years that have studied the effect of ethnic factors on drug responses and identified practical challenges in conducting MRCTs in Asia. This mini‐review highlights these research outcomes and related articles and presents our perspective on the current situation and future direction of MRCTs to explore opportunities for more collaboration between Japan and other East Asian/South‐East Asian countries to facilitate drug development.


  • Open Access

    Expediting Drug Development in Japan: A PMDA Perspective

    by Yoichi Kohno, Akihiro Ishiguro, Takashi Yasukawa, Naoyuki Yasuda, Daisuke Tanaka, Yasuhiro Araki, Yukio Takahashi, Yoshiaki Uyama, Yasuhiro Fujiwara

    Review time for a new drug in Japan has shortened dramatically since the establishment of the Pharmaceuticals and Medical Devices Agency (PMDA). Nonetheless, Japan faces a new challenge so‐called “Drug Loss”, which means that new drugs approved overseas have not yet been developed in Japan or that development is delayed. In this manuscript, we describe how PMDA facilitates Japan’s drug development to continuously provide innovative drugs to patients.


  • Characteristics of Multi-Regional Clinical Trials Conducted in Asia, Focusing on Japan’s Participation and Small/Medium Companies-Sponsored Trials

    by Akihito Kojima, Hideki Hanaoka, Yoshiaki Uyama

    Background Less participation by Japan in multi-regional clinical trials (MRCTs) is one of concerns that leads to drug loss in Japan, but the characteristics of Japan’s participation in MRCTs have not been well studied. Purpose This study investigated Japan’s situation in global drug development by characterizing its participation in MRCTs compared with East and South-East Asian countries/regions, with a focus on MRCTs sponsored by small-medium companies to discuss necessary measures in further promoting drug development in Japan. Methods Data from MRCTs conducted in East and South-East Asia during the period from January 1, 2013 to December 31, 2022 were analyzed. Results Japan’s participation in MRCTs conducted in Asia (East Asia and South-East Asia) was limited. In particular, Japan participated in only 15–16% of MRCTs sponsored by Small/Medium-pharma (mainly US-based companies), with even less participation in Early Phase MRCTs. Japan’s participation in MRCTs was markedly lower than other Asian countries/regions such as Singapore, South Korea, and Taiwan, although it was relatively higher in MRCTs that targeted neoplasms compared with other diseases. Conclusion Results of this study raise significant concern about future potential drug loss in Japan. It is urgent to increase the participation of Japan in MRCTs in order to continuously provide new globally developed drugs to patients in Japan. For that purpose, an integrated approach that includes continuous improvement in pharmaceutical regulations and the clinical trial environment, as well as market attractiveness, will be necessary in parallel with strengthening of collaborations between Japan and other Asian countries/regions.